
Heather Adkins - Ꜻ - Spes consilium non est
6.5K posts

Heather Adkins - Ꜻ - Spes consilium non est
@argvee
VP Security @Google, Co-Author "Building Secure and Reliable Systems" @r00t0wns, Medieval Historian


This is just so brilliant… wow🔥 England 🏴 vs Norway 🇳🇴 Credit: @higgsfield



Ukrainians have launched a new online “game”: changing fuel station statuses on maps, marking empty stations as supplied and supplied stations as empty. The result is chaos in Moscow: drivers waste time, burn extra fuel, create traffic jams, and clash at gas stations.

"In a private Telegram channel, the group is offering $500 to people to visit law firms and plug in USB sticks, one cybersecurity professional familiar with the incidents told CNN." cnn.com/2026/06/27/pol…


I'm a cardiologist. NPR reported this morning on something that could save more lives than any drug I've ever prescribed. One blood test. One vial. Screening for 50 different cancers simultaneously. It's called Galleri. And the FDA could approve it later this year. Right now, we routinely screen for exactly five cancers in the United States — breast, colon, cervical, prostate, and lung. Each requires its own separate scan or exam. For the rest — pancreatic cancer, ovarian cancer, liver cancer, esophageal cancer, gastric cancer, and dozens more — we have no routine screening at all. We find them when symptoms appear. By then, most are Stage 3 or 4. By then, for many patients, it's too late. Pancreatic cancer has a 12% five-year survival rate — because we almost always catch it late. Ovarian cancer: 50%. Liver cancer: 21%. These numbers aren't medical failures. They're detection failures. The treatments exist. We just find the disease after the window for those treatments has closed. Galleri changes the math entirely. Here's how it works. Every tumor — no matter where it is in your body — sheds tiny fragments of DNA into your bloodstream as cancer cells die and divide. These fragments carry specific methylation patterns — chemical signatures that are unique to cancer cells and different from the DNA your healthy cells release. Galleri captures these fragments from a standard blood draw and reads their methylation patterns using next-generation sequencing and AI-driven analysis. The AI doesn't just detect whether cancer is present. It predicts where it's coming from — which organ, which tissue type — with over 90% accuracy in studies. One vial of blood tells your doctor: there's a cancer signal, and it's likely originating in your pancreas, or your lung, or your liver. Your physician then orders targeted follow-up imaging to confirm or rule out the finding. Galleri isn't a diagnosis. It's a precision compass that tells your doctor exactly where to look. The data is building fast. GRAIL has now sold over 475,000 Galleri tests commercially under a special FDA designation. The NHS-Galleri trial — the largest randomized controlled trial of any multi-cancer detection test in history — enrolled over 142,000 people aged 50-77 in England. The primary endpoint — an overall reduction in late-stage cancers — was not met. But by the third year of annual screening, they found a 26% reduction in Stage IV cancers in key deadly types including pancreatic, liver, lung, and gastric. The test detected four times more cancers overall when added to standard screening — catching cancers that would otherwise have been found late or not at all. The U.S. Pathfinder 2 study — 25,490 participants — showed similar positive signals and forms the basis of the FDA submission filed in January 2026. Congress has already acted. The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act passed in February. If the FDA approves Galleri, Medicare will begin covering one test per year starting in 2028. The current retail price is $950. Exact Sciences' competing test Cancerguard is $659. These prices will fall dramatically once FDA approval triggers insurance coverage and competition scales. As a cardiologist, let me tell you why this matters far beyond oncology. Cancer is now the number one killer of Americans over 50. Not heart disease. Cancer. And the patients I lose to cancer are often the same patients whose hearts I saved — patients who survived their cardiac event, optimized their metabolic health, and then received a late-stage cancer diagnosis that nobody screened for because no screening tool existed. I've written on this platform about GLP-1 drugs reducing cancer metastasis by up to 50%. About personalized mRNA cancer vaccines cutting recurrence by 49%. About inflammation as the common root of heart disease and cancer. About AI detecting disease years before symptoms. Galleri is the missing piece that connects all of it. Detect the cancer early — with a blood test. Confirm it with AI-enhanced imaging. Treat it with personalized mRNA vaccines, targeted therapy, and GLP-1 drugs that may slow progression. Monitor response with liquid biopsy in real time. That's not five separate breakthroughs. That's one integrated system of cancer prevention and treatment that didn't exist five years ago — and could be standard of care within five more. The shift from reactive to proactive medicine — from "we found it too late" to "we caught it in time" — has been the central theme of everything I've written on this platform. Preventive cardiology. Advanced lipid testing. Inflammation detection. AI imaging. Gene editing. Galleri applies the same principle to cancer. And it could save more lives than all of them combined. One blood test. Fifty cancers. FDA decision expected this year. Prevention is the new cure. And the science just took its biggest step yet. open.substack.com/pub/afshine/p/…










